Sokolová Šidlová J, Synek S, Zampachová E, Beneš P, Matúšová J
Cesk Slov Oftalmol. 2014 Feb;70(1):15-20.
Aim of the paper is to introduce and evaluate the microperimetry as a support technique in the evaluation of the ARMD wet form bevacizumab (Avastin) treatment efficacy.
Twenty-one patients (21 eyes) with ARMD wet form were included in the study; they were examined by means by OCT/SLO (optic coherence tomography / scanning laser ophthalmoscope) machine whose part is the microperimetric test. In each patient, there were two microperimetric examinations performed - the first one was done one day before the application of the treatment and the second one one month after the application. The values of retinal sensitivity and possible absolute scotomas were recorded by the microperimeter. The best-corrected visual acuity measurement was recorded as well.
The measurements were performed in the group of 21 eyes of 8 men and 13 women (age 50 - 86 years). There were the differences between the genders evaluated (at the selected level of significance of 0.05) in the following categories: age, retinal sensitivity, absolute scotoma extent, and visual acuity. Differences among men and women were found in retinal sensitivity, before the treatment and after it as well. The influence of the gender we may exclude, except the category of retinal sensitivity. In the categories age, visual acuity, and even absolute scotoma extent, no differences between genders were found. The retinal sensitivity (in case of fixation up to 4 degrees) improved in the men group from 14.49 dB ± 2.44 dB to 15.65 dB ± 2.61 dB, in the women group from 10.47 dB ± 3.11 dB to 12.05 dB ± 3.10 dB. The visual acuity in the whole group (men + women) increased from 0.48 ± 0.17 to 0.60 ± 0.18, so improved by 12 %. Statistically significant is also the result of the treatment in the absolute scotoma.
Microperimetry is a suitable method to evaluate the function of macular region of the retina. The study confirms, that the treatment of wet form ARMD by means of intravitreal bevacizumab injections significantly increases the retinal sensitivity (in dB), decreases of the extent of absolute scotoma and improves the visual acuity by 12 %.
本文的目的是介绍和评估微视野检查法作为评估湿性年龄相关性黄斑变性（ARMD）贝伐单抗（阿瓦斯汀）治疗效果的辅助技术。
纳入21例湿性ARMD患者（21只眼）；使用包含微视野检查测试的光学相干断层扫描/扫描激光检眼镜（OCT/SLO）机器对他们进行检查。对每位患者进行两次微视野检查——第一次在治疗前一天进行，第二次在治疗后一个月进行。微视野计记录视网膜敏感度值和可能存在的绝对暗点。同时记录最佳矫正视力测量结果。
对8名男性和13名女性（年龄50 - 86岁）的21只眼进行了测量。在以下类别中评估了性别差异（在选定的0.05显著性水平下）：年龄、视网膜敏感度、绝对暗点范围和视力。在治疗前和治疗后，男性和女性在视网膜敏感度方面均存在差异。除视网膜敏感度类别外，我们可以排除性别影响。在年龄、视力甚至绝对暗点范围类别中，未发现性别差异。男性组中，视网膜敏感度（注视范围达4度时）从14.49 dB ± 2.44 dB提高到15.65 dB ± 2.61 dB，女性组从10.47 dB ± 3.11 dB提高到12.05 dB ± 3.10 dB。整个组（男性 + 女性）的视力从0.48 ± 0.17提高到0.60 ± 0.18，提高了12%。治疗在绝对暗点方面的结果也具有统计学意义。
微视野检查法是评估视网膜黄斑区功能的合适方法。该研究证实，通过玻璃体内注射贝伐单抗治疗湿性ARMD可显著提高视网膜敏感度（以dB为单位），减小绝对暗点范围，并使视力提高12%。
